3 results
Primary: efficacy and safety of the addition of UMEC 62.5mcg once daily to ICS/LABA therapy, compared with placebo over 12 weeks in subjects with COPD.Secondary: effect of the addition of UMEC to ICS/LABA therapy on COPD-related health status…
This is a phase I study of hydroxyurea and dose-intense temozolomide in patients with recurrent glioblastoma that are elegise for re-challenge temozolomide.Primary Objective: To determine the maximal tolerated dose and safety profile of daily…
Part ATo evaluate the safety and tolerability of single and split intravenous doses of Apta-1 in healthy volunteers.Part BTo evaluate the safety and tolerability of split intravenous doses of Apta-1 after LPS infusion in healthy volunteers.